Related Experiment Video
Updated: May 21, 2026
05:51
Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease
Published on: October 14, 2021
Cysteine decrease following acute Levodopa intake in patients with Parkinson's disease
Thomas Müller1, Siegfried Muhlack
1Department of Neurology, St. Joseph Hospital Berlin-Weissensee, Gartenstr. 1, 13088 Berlin, Germany. th.mueller@alexius.de
Neuroscience Letters
|May 30, 2012
Summary
Levodopa (LD) treatment in Parkinson's patients decreased plasma free cysteine levels. This suggests LD may increase oxidative stress by upregulating glutathione (GSH) synthesis to combat free radicals.
Area of Science:
- Neuroscience
- Biochemistry
- Pharmacology
Background:
- Thiol homeostasis is crucial for redox balance and free radical scavenging by antioxidants like glutathione (GSH).
- Increased free radical production is a hallmark of chronic neurodegenerative diseases.
- Levodopa (LD) is suspected to promote free radical synthesis through dopamine metabolism in mitochondria.
Purpose of the Study:
- To investigate the effect of Levodopa/Carbidopa (LD/CD) administration on plasma free cysteine levels in Parkinson's disease patients.
- To explore the potential link between LD, oxidative stress, and cysteine metabolism.
Main Methods:
- 13 Parkinson's disease patients received a single dose of 200mg LD/50mg CD.
- Plasma levels of LD and free cysteine were measured at baseline, 60 minutes, and 80 minutes post-administration.
Main Results:
- Plasma Levodopa (LD) levels increased significantly after administration.
- Plasma free cysteine concentrations showed a noticeable decrease following LD/CD treatment.
- The observed decrease in cysteine suggests increased utilization.
Conclusions:
- Levodopa (LD) administration appears to decrease plasma free cysteine levels in Parkinson's patients.
- This cysteine reduction may indicate an upregulation of glutathione (GSH) synthesis.
- This response could be a mechanism to counteract increased free radical generation associated with Levodopa (LD) metabolism.
Related Concept Videos
01:24Parkinson's Disease: Treatment
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
01:24Parkinson Disease ll: Pathophysiology
Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
01:15Parkinson's Disease: Overview
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
01:22Lysosomal Hydrolases
Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
01:24Parkinson Disease l: Introduction
Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of which...
01:11Alterations in Muscle Tone lll
Rigidity and myotonia are distinct abnormalities of muscle tone that affect resistance and relaxation during movement. Although both involve altered muscle contraction, they arise from different neurological and muscular mechanisms.CharacteristicsRigidity is characterized by uniform resistance to passive movement across the entire range, independent of speed, affecting flexors and extensors equally. It may appear as lead-pipe rigidity (smooth, constant resistance) or cogwheel rigidity...